The Site Initiation Visit and Getting Ready to Enroll

Part of Clinical Research Coordinator (CRC) Training: Study Start-Up at the Site.

About 5 minutes. Free, in your language, no account needed.

Why this matters

Between "your site is selected" and "you may enroll your first participant" sits a list of things that must all be true at once. Miss one and either you cannot start, or worse, you start when you should not have.

This lesson is that list, and the visit at the end of it.

What must be in place before enrollment

A site is normally activated — sometimes called "green light" — only when all of the following are true.

• Ethics committee approval for the protocol, the consent form and any participant-facing material, in the versions the site will use.
• Regulatory authorization for the trial, held by the sponsor.
• A fully executed clinical trial agreement. Signed by all parties. Not "in final review".
• Essential records collected: CVs, licenses, training records, delegation log, financial disclosures, laboratory accreditation and reference ranges.
• Staff trained on the protocol and on the study systems, with the training documented.
• The site initiation visit completed.
• Investigational product released and received, with storage confirmed.
• Systems access granted for everyone who needs it, with individual accounts.

The last point deserves emphasis: no shared logins, ever. A shared account destroys attribution, which is one of the data integrity attributes E6(R3) requires.

Enrolling before activation is one of the most serious deviations a site can commit, because everything that follows for that participant is affected.

The site initiation visit

The site initiation visit, or SIV, is the meeting at which the sponsor or contract research organization trains the site and confirms readiness. It may be on site or remote.

Who should attend: the principal investigator, every sub-investigator, all coordinators, and the pharmacy and laboratory staff who will touch the study. If a key person cannot attend, agree in advance how they will be trained and how that training will be documented — not afterwards.

What is normally covered:

• The protocol in detail: objectives, design, eligibility, the schedule of assessments, dosing.
• The informed consent process and the site's specific arrangements for it.
• Safety definitions and reporting, including who to contact and by when.
• Source documentation expectations and the source data location list.
• The electronic data capture system and any other systems, with hands-on practice.
• Investigational product handling: receipt, storage, temperature monitoring, dispensing, accountability, returns.
• Laboratory procedures: kits, processing, labeling, shipping.
• The monitoring plan: how often visits will happen and what will be reviewed.
• Roles, escalation routes and contact details.

What the site should do before the visit

• Read the protocol properly. The SIV is far more useful when questions are already written down.
• Prepare source worksheets that follow the schedule of assessments, so nothing is collected on scrap paper.
• Draft the source data location list: for each protocol data point, where the source lives and how it is captured. E6(R3) section 2.12.2 requires the investigator to define this before the trial starts.
• Check equipment calibration and storage temperature monitoring.
• Confirm who is on the delegation log and that everyone has an account for the study systems.
• Prepare the recruitment plan, including how eligible people will be identified.

What to do immediately after

• File the SIV documentation, including the attendance and training record.
• Complete training for anyone who missed it, and document it.
• Resolve every open action before enrolling, or record why it is acceptable to proceed.
• Confirm in writing that the site is activated. Do not infer activation from a friendly email.
• Do a dry run: walk one imaginary participant through screening, consent, randomization and visit 1, and see what is missing.

The dry run is the single most useful hour a coordinator can spend before their first participant.

In practice

Northside Clinic completes its SIV for VT-201 on a Thursday. Marcus, the monitor, leaves three open actions: the pharmacy fridge needs a second temperature probe, one sub-investigator missed the training, and the site has not yet been given accounts for the randomization system.

The following Monday a strong candidate calls, having seen the study advertised, and asks to come in that afternoon.

Nadia does not book a screening visit. She books the appointment for the following week, explains that the site is not yet ready to start, and uses the intervening days to close the three actions and to obtain written confirmation of activation.

She then does the dry run and finds a fourth problem nobody had spotted: the source worksheet has no field for the time of the second blood pressure reading, which the protocol requires. She fixes it in an afternoon.

Her first real participant is screened with a complete worksheet, on a system she has used, at an activated site.

The pressure to start early is real, and it is always cheaper to resist it than to unwind it.

Key takeaways

• A site may not enroll before activation, which requires ethics approval, an executed contract, collected essential records, documented training, a completed initiation visit and released product.
• Every user needs an individual system account, because shared logins destroy attribution, one of the data integrity attributes ICH E6(R3) requires.
• The site initiation visit trains the whole site team, and anyone who misses it must be trained and documented before performing study tasks.
• E6(R3) section 2.12.2 requires the investigator to define the source records, how they are captured and where they are held, before the trial starts.
• A dry run through screening, consent, randomization and the first visit reliably exposes gaps while they are still cheap to fix.